2024
Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study
Petrakis I, Nolen T, Vandergrift N, Hirsch S, Krystal J, De Vivo M, Sabados J, Pisani E, Newcomb J, Kosten T. Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study. American Journal On Addictions 2024 PMID: 39152094, DOI: 10.1111/ajad.13637.Peer-Reviewed Original ResearchPathophysiology of posttraumatic stress disorderAlcohol use disorderSubjective effects of alcoholEffects of alcoholUse disorderComorbid alcohol use disorderAlcohol cue reactivityPosttraumatic stress disorderCrossover laboratory studyCue reactivityAlcohol cravingNoradrenergic dysregulationStress disorderBlood pressureSubjective effectsEthanol administrationClinically significant adverse effectsPharmacotherapeutic approachesTest daysReceptor agonistsPotential treatmentDouble-blind fashionCravingDrinking alcoholDisordersThe combination of donepezil and cognitive training for improving treatment outcomes for alcohol use disorder: Design of a randomized controlled trial
Yoon G, Sofuoglu M, Petrakis I, Pittman B, Bell M. The combination of donepezil and cognitive training for improving treatment outcomes for alcohol use disorder: Design of a randomized controlled trial. Contemporary Clinical Trials 2024, 145: 107657. PMID: 39111388, PMCID: PMC11423257, DOI: 10.1016/j.cct.2024.107657.Peer-Reviewed Original ResearchCognitive remediation therapyAlcohol use disorderAlcohol use disorder treatment outcomesNeurocognitive functionCombination of donepezilRemediation therapyUse disorderTreatment outcomesDevelopment of alcohol use disordersReduce heavy drinking daysHeavy drinking daysGlobal neurocognitive functioningImprove neurocognitive functionEnhanced neurocognitive functionImprove cognitive functionRandomized controlled trialsReduce alcohol consumptionNeurobiological evidenceDrinking daysNeurocognitive function scoresCognitive trainingVA Connecticut Healthcare SystemCognitive functionImprove treatment outcomesCognitive impairmentAlcohol Use Disorder and Chronic Pain: An Overlooked Epidemic
De Aquino J, Sloan M, Nunes J, Costa G, Katz J, de Oliveira D, Ra J, Tang V, Petrakis I. Alcohol Use Disorder and Chronic Pain: An Overlooked Epidemic. American Journal Of Psychiatry 2024, 181: 391-402. PMID: 38706339, PMCID: PMC11521207, DOI: 10.1176/appi.ajp.20230886.Peer-Reviewed Original ResearchConceptsAlcohol use disorderChronic painAUD studiesChronic pain disordersChronic pain outcomesRisk of relapseAlcohol withdrawal syndromeAssessment of painHigher levels of alcohol consumptionLevels of alcohol consumptionWithdrawal syndromePain disordersPain outcomesAcute toleranceNeurobiological changesClinical significanceUse disorderPainClinical relevanceSelf-reportAlcohol intoxicationAlcohol consumptionGeneral populationMedical conditionsNarrative reviewProblem Opioid Use Among US Military Veterans: Prevalence, Correlates, and Psychiatric Characteristics
Na P, Petrakis I, Krystal J, Pietrzak R. Problem Opioid Use Among US Military Veterans: Prevalence, Correlates, and Psychiatric Characteristics. Journal Of Addiction Medicine 2024, 18: 313-318. PMID: 38498625, PMCID: PMC11150085, DOI: 10.1097/adm.0000000000001286.Peer-Reviewed Original ResearchInstrumental activities of daily livingInstrumental activities of daily living disabilityLifetime suicide attemptsProblem opioid useUS military veteransUS veteransPsychiatric characteristicsSuicide attemptsMilitary veteransAssociated with black race/ethnicityActivities of daily livingNational Health and ResilienceLifetime alcohol use disorderMental health morbidityPosttraumatic stress disorderMental health disordersAlcohol use disorderNon-Hispanic race/ethnicityMultivariate logistic regression modelNationally representative sampleOpioid useLogistic regression modelsInstrumental activitiesHealth morbidityDaily livingThe role of neurosteroids in posttraumatic stress disorder and alcohol use disorder: A review of 10 years of clinical literature and treatment implications
Peltier M, Verplaetse T, Altemus M, Zakiniaeiz Y, Ralevski E, Mineur Y, Gueorguieva R, Picciotto M, Cosgrove K, Petrakis I, McKee S. The role of neurosteroids in posttraumatic stress disorder and alcohol use disorder: A review of 10 years of clinical literature and treatment implications. Frontiers In Neuroendocrinology 2024, 73: 101119. PMID: 38184208, PMCID: PMC11185997, DOI: 10.1016/j.yfrne.2023.101119.Peer-Reviewed Original ResearchPosttraumatic stress disorderAlcohol use disorderStress disorderContext of PTSDPTSD/AUDConcurrent posttraumatic stress disorderUnderlying neurobiological mechanismsUse disordersAlcohol-related variablesNeurobiological mechanismsPTSD diagnosisTreatment developmentTreatment implicationsBody of literatureNovel interventionsClinical literatureRole of neurosteroidsDisordersTreatment outcomesYears of researchAlcohol consumptionExogenous pregnenolonePharmacological treatmentBiological variablesAllopregnanolone
2023
Progesterone Attenuates the Stress Response in Individuals with Alcohol Dependence and Post-Traumatic Stress Disorder – A Pilot Study
Ralevski E, Newcomb J, Pisani E, DeNegre D, Peltier M, Jane J, Yoon G, Petrakis I. Progesterone Attenuates the Stress Response in Individuals with Alcohol Dependence and Post-Traumatic Stress Disorder – A Pilot Study. Journal Of Dual Diagnosis 2023, 20: 39-51. PMID: 38147491, PMCID: PMC11214330, DOI: 10.1080/15504263.2023.2294989.Peer-Reviewed Original ResearchAlcohol use disorderStress-induced cravingCognitive performanceNegative affectNeutral scriptsStress disorderPost-traumatic stress disorderComorbid alcohol use disorderTraumatic Stress DisorderMeasures of cravingCurrent alcohol use disorderPositive emotionsTrauma scriptsPhysiological measuresCravingStress-induced symptomsTest sessionsPTSDAnxietyAffectUse disordersLaboratory sessionsCocaine dependenceAlcohol dependenceIndividualsComorbid alcohol use disorder and posttraumatic stress disorder: A proof‐of‐concept randomized placebo‐controlled trial of buprenorphine and naltrexone combination treatment
Davis L, Petrakis I, Pilkinton P, Nolen T, Vandergrift N, Hirsch S, Norrholm S, Kosten T. Comorbid alcohol use disorder and posttraumatic stress disorder: A proof‐of‐concept randomized placebo‐controlled trial of buprenorphine and naltrexone combination treatment. Alcohol Clinical And Experimental Research 2023, 47: 1756-1772. PMID: 37468230, DOI: 10.1111/acer.15155.Peer-Reviewed Original ResearchComorbid alcohol use disorderAlcohol use disorderPosttraumatic stress disorderPlacebo-controlled trialWorld Health OrganizationReceptor antagonismOpioid receptorsUse disordersExtended-release injectable naltrexoneKappa-opioid receptor antagonistStress disorderClinician-Administered PTSD ScalePrimary composite outcomeEffective pharmacologic treatmentOpioid receptor antagonistOpioid receptor antagonismMu-opioid receptorsCombination of buprenorphineBinary primary outcomeTimeline Follow-BackAUD outcomesBuprenorphine 2Injectable placeboPrimary timepointInjectable naltrexoneTrajectories of alcohol consumption in U.S. military veterans: Results from a 10-year population-based longitudinal study
Na P, Montalvo-Ortiz J, Petrakis I, Krystal J, Polimanti R, Gelernter J, Pietrzak R. Trajectories of alcohol consumption in U.S. military veterans: Results from a 10-year population-based longitudinal study. Drug And Alcohol Dependence 2023, 246: 109833. PMID: 36963160, PMCID: PMC10811960, DOI: 10.1016/j.drugalcdep.2023.109833.Peer-Reviewed Original ResearchConceptsAlcohol consumption groupCurrent mental health treatmentDysphoric arousal symptomsMental health treatmentUS veteransAlcohol consumptionHealth treatmentConsumption groupArousal symptomsYounger agePopulation-based longitudinal studyPublic health problemLongitudinal studyExcessive alcohol consumptionAlcohol use disorderPosttraumatic stress disorderU.S. military veteransMedical comorbiditiesChronic courseNational HealthClose monitoringUse disordersHealth problemsVeterans StudyStress disorder
2020
Alcohol
Sloan M, Werner R, Yarnell-MacGrory S, Petrakis I. Alcohol. 2020, 121-137. DOI: 10.1007/978-3-030-33404-8_8.Peer-Reviewed Original ResearchAlcohol use disorderUse disordersIndirect laboratory testsWithdrawal symptomsPhysiologic dependenceClinical managementLeading causeGlutamatergic synapsesDiagnostic criteriaAlcohol consumptionAlcohol intoxicationHeavy drinkersRecent consumptionAlcohol useAltered activityRecent evidenceSymptomsLoss of controlIntoxicationSynapsesDisordersWithdrawalLaboratory testsGABAergicPharmacotherapy
2019
Pharmacotherapies for PTSD and Substance Use Disorders
Kachadourian L, Jensen K, Sofuoglu M, Petrakis I. Pharmacotherapies for PTSD and Substance Use Disorders. 2019, 239-259. DOI: 10.4324/9781315442648-13.ChaptersOpioid use disorderAlcohol use disorderPosttraumatic stress disorderUse disordersPTSD/SUDPharmacological treatmentComorbid posttraumatic stress disorderUse of pharmacotherapySubstance use disordersEffectiveness of foodIntramuscular naltrexoneLabel medicationsEpidemiological studiesMedication developmentDrug AdministrationPharmacotherapyStress disorderAvailable evidenceDisordersNew targetsNaltrexoneTreatmentBiological mechanismsSpecific substancesSUDChapter 13 Trauma and Addiction—How to Treat Co-occurring PTSD and Substance Use Disorders
Vojvoda D, Petrakis I. Chapter 13 Trauma and Addiction—How to Treat Co-occurring PTSD and Substance Use Disorders. 2019, 189-196. DOI: 10.1016/b978-0-323-54856-4.00013-4.Peer-Reviewed Original ResearchSubstance use disordersAlcohol use disorderPosttraumatic stress disorderComorbid substance use disorderPTSD symptomsCo-occurring posttraumatic stress disorderRandomized clinical studyWorse clinical outcomesTreatment of patientsSeverity of AUDSeverity of symptomsCo-occurring disordersReduction of severityRecent pharmacological advancesAnticonvulsant topiramateClinical outcomesPharmacological treatmentPTSD comorbidityClinical studiesPharmacological advancesInconstant effectsMedicationsUse disordersAlcohol consumptionN-acetylcysteine
2018
Pharmacological and Psychological Treatments for Comorbid Alcohol Use Disorder and Depressive Disorder: a Review
Yoon G, Petrakis I. Pharmacological and Psychological Treatments for Comorbid Alcohol Use Disorder and Depressive Disorder: a Review. Current Addiction Reports 2018, 5: 312-322. DOI: 10.1007/s40429-018-0213-z.Peer-Reviewed Original ResearchComorbid alcohol use disorderAlcohol use disorderPsychological interventionsCognitive-behavioral treatmentUse disordersPsychological treatmentDepressive disorderMotivational interviewingComorbid disordersMixed resultsDisordersInterventionRecent FindingsWePharmacological interventionsCurrent reviewEffective treatmentFurther researchReviewThe goalInterviewingAntidepressantsPatientsTreatmentDepressionTrialsEfficacy
2016
Alcohol Use Disorders and Comorbid Post-Traumatic Stress Disorder in US Military Veterans: Etiology and Current Treatment Approaches
Kachadourian L, McCarthy E, Petrakis I. Alcohol Use Disorders and Comorbid Post-Traumatic Stress Disorder in US Military Veterans: Etiology and Current Treatment Approaches. 2016, 627-642. DOI: 10.1007/978-3-319-08359-9_108.ChaptersPost-traumatic stress disorderAlcohol use disorderComorbid post-traumatic stress disorderUse disordersAlcohol dependenceStress disorderCurrent treatment approachesSubstance use disordersUS military veteransPharmacological interventionsDual diagnosisTreatment approachesDisordersPotential mechanismsMilitary veteransHigh ratePsychotherapeutic approachesComorbiditiesEtiologyDiagnosis
2015
Alcohol Use Disorders and Comorbid Posttraumatic Stress Disorder in US Military Veterans: Etiology and Current Treatment Approaches
Kachadourian L, McCarthy E, Petrakis I. Alcohol Use Disorders and Comorbid Posttraumatic Stress Disorder in US Military Veterans: Etiology and Current Treatment Approaches. 2015, 1-13. DOI: 10.1007/978-3-319-08613-2_108-1.Peer-Reviewed Original ResearchAlcohol use disorderPosttraumatic stress disorderComorbid posttraumatic stress disorderUse disordersAlcohol dependenceStress disorderCurrent treatment approachesSubstance use disordersUS military veteransPharmacological interventionsDual diagnosisTreatment approachesDisordersPotential mechanismsMilitary veteransHigh ratePsychotherapeutic approachesComorbiditiesEtiologyDiagnosis
2013
Chapter 38 Disulfiram for Alcohol and Other Drug Use
Kerfoot K, Petrakis I. Chapter 38 Disulfiram for Alcohol and Other Drug Use. 2013, 367-374. DOI: 10.1016/b978-0-12-398338-1.00038-5.Peer-Reviewed Original ResearchUse disordersEfficacy of disulfiramAlcohol use disorderClinical research studiesCocaine use disorderDisulfiram useFirst medicationCardiorespiratory collapseIngested alcoholRare caseDrug AdministrationUS FoodDrug useAlcohol dependenceAddiction treatmentDisulfiramTreatmentNormal metabolismDisordersPositive outcomesPotential usefulnessNauseaMedicationsHeadacheAdministration
2009
Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers
McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, Picciotto MR, Petrakis IL, Estevez N, Balchunas E. Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers. Biological Psychiatry 2009, 66: 185-190. PMID: 19249750, PMCID: PMC2863311, DOI: 10.1016/j.biopsych.2009.01.029.Peer-Reviewed Original ResearchConceptsHeavy drinking smokersSelf-administration periodAlcohol consumptionPartial nicotinic agonistPlacebo-controlled investigationEffects of vareniclineReduced ethanol intakeAlcohol Self-AdministrationAlcohol use disorderNicotinic acetylcholine receptorsMedication pretreatmentAdverse eventsNumber of drinksPreclinical evidenceAdditional drinkEthanol intakeTobacco dependenceDaily smokersPriming doseVareniclineComorbid disordersNicotinic agonistsUse disordersPriming drinkPotential treatmentPharmacotherapeutic Effects of Opioid Antagonists in Alcohol-Abusing Patients with Schizophrenia
Petrakis I. Pharmacotherapeutic Effects of Opioid Antagonists in Alcohol-Abusing Patients with Schizophrenia. Contemporary Neuroscience 2009, 473-483. DOI: 10.1007/978-1-59745-197-0_25.Peer-Reviewed Original ResearchAlcohol use disorderOpioid antagonist naltrexoneUse disordersAntagonist naltrexoneTherapeutic optionsGeneral populationSchizoaffective disorderDevastating clinical disorderOpioid antagonist treatmentBest therapeutic optionGroup of patientsUse of naltrexoneSymptoms of psychosisNoncomorbid patientsPharmacologic managementAntagonist treatmentOpioid antagonistAlcohol use/dependenceComorbid schizophreniaClinical trialsPharmacotherapeutic effectsSchizophrenic patientsPatientsSide effectsCognitive symptoms